A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Neeta Somaiah, Sant P. Chawla, Matthew S. Block, John C. Morris, Khanh Do, Joseph W. Kim, Mihaela Druta, Kamalesh K. Sankhala, Patrick Hwu, Robin L. Jones, Sacha Gnjatic, Seunghee Kim-Schulze, Kevin Tuballes, Mahlet Yishak, Hailing Lu, Adam Yakovich, Jan Ter Meulen, Michael Chen, Richard T. Kenney, Chet BohacSeth M. Pollack

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1'. Together they form a unique fingerprint.

Medicine & Life Sciences